A Leading Cause of Death in COVID-19 Infected Individuals

Virus-induced Cytokine Storm (VICS) is associated with high mortality rates and is defined by an excess production of inflammatory cytokines in response to a virulent viral infection. As the vast majority of human viruses are not addressed with a corresponding drug or vaccine, there is an urgent and ongoing need for therapies that mitigate the Cytokine Storm that can be initiated by a broad-spectrum of viral pathogens.

The COVID-19 Cytokine Storm

Virus-induced Cytokine Storm is a leading cause of COVID-19 deaths and often precipitates other life-threatening conditions including acute respiratory distress syndrome (ARDS) and sepsis, which are highly prevalent in hospitalized COVID-19 patients. 

In March of 2020, Yale University researchers reported that elevated levels of pro-inflammatory cytokines correlated with the severity of COVID-19 infection and increased mortality rates. Inversely, the researchers reported that declining levels of these same cytokines are associated with patient recovery.

The Annual Burden of VICS Related Deaths

Beyond COVID-19, virus-induced Cytokine Storm is associated with many of the 250,000 to 500,000 global deaths that result from severe influenza infections each year. In some years, the death toll resulting from influenza rises to pandemic proportions. In modern history, the best-known example is the H1N1 Spanish Flu of 1918 which caused the deaths of more than 50 million individuals. In recent years, virus-induced Cytokine Storm was also associated with high mortality resulting from the 2003 SARS virus outbreak and the 2014-15 Ebola virus outbreak, among others.

An Unmet Need for Life-threatening Inflammatory Conditions

In the absence of an antiviral drug or vaccine to combat severe viral infections, there is an urgent unmet need for therapies to address life-threatening inflammatory conditions that manifest in individuals after infection. 

Sigyn Therapy is designed to be a first-line countermeasure to mitigate Cytokine Storm Syndrome in emerging viral outbreaks that are increasingly being fueled by a confluence of global warming, urban crowding, and intercontinental travel. As it is improbable for disease-specific drugs and vaccines to be developed, proven effective, manufactured and then delivered within a time frame necessary to combat an emerging pandemic, there will be a continued need for therapies to address virus-induced Cytokine Storm Syndrome.